141 results
424B3
KA
Kineta Inc
13 Nov 23
Prospectus supplement
5:28pm
and our ability to access capital markets;
the effect of COVID-19 on the foregoing; and
other risks and uncertainties, including those listed under
8-K
EX-10.1
3ff1 mvuc9v9
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
vnc3uxsgaj
5 Oct 23
Prospectus supplement for primary offering
10:47am
424B3
15hyp0 fh9
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-10.1
7xiyjh000cwr8roy iu
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
424B5
6j8t0769pzmrzep9j
21 Apr 23
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.6
ecio8g3i
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.2
1yu9cfut 7q
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.5
y2fnm58dzujo5s4dmuf
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-3.3
pn0h2lu c4jzi73d
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm